Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn.
Resected carcinoma patients were immunized 3-5 times with ovine submaxillary gland mucin (OSM) containing predominantly sialylated Tn (sTn), completely desialylated ovine submaxillary gland mucin (dOSM) containing predominantly Tn, or 50% desialylated OSM containing Tn and sTn plus bacillus Calmette-Guerin (BCG) as an immunologic adjuvant. Pre- and postimmunization sera were quantified by ELISA, whole-cell ELISA, and immune stain dot blots. Fifteen of 17 patients produced IgG antibody titers from 40 to 5120 times more reactive with OSM and dOSM postimmunization. More importantly, these IgG antibodies reacted with LS-174T, a human colon carcinoma cell line. Significant DTH-like responses (1-17 cm) were observed in 15 of 17 patients; the strength of these responses was dependent on the presence or absence of sialic acid. Biopsies of these DTH-like reactions revealed infiltration with some CD8+ lymphocytes and mast cells. These results suggest that a single 9-carbon sugar can affect cellular immune responses to mucin antigens. It is thought that these large erythematous, nonindurated cellular reactions are antibody-mediated Arthus-like reactions. OSM, and especially dOSM, were also found to inhibit lymphocyte proliferation.
O'Boyle
Kevin P
KP
Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA. mdoboyle2004@yahoo.com
Coatsworth
Susan
S
Anthony
Gillian
G
Ramirez
Mark
M
Greenwald
Edward
E
Kaleya
Ronald
R
Steinberg
Jacob J
JJ
Dutcher
Janice P
JP
Wiernik
Peter H
PH
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D000917:Antibody Formation; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000737:chemistry / Q000276:immunology*; D001500:BCG Vaccine / Q000008:administration & dosage; D018414:CD8-Positive T-Lymphocytes; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use*; D002277:Carcinoma / Q000276:immunology* / Q000628:therapy*; D049109:Cell Proliferation; D003110:Colonic Neoplasms; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007111:Immunity, Cellular; D007074:Immunoglobulin G / Q000032:analysis; D008407:Mast Cells; D009077:Mucins / Q000276:immunology* / Q000627:therapeutic use*; D013363:Submandibular Gland / Q000737:chemistry; D013552:Swine; D014407:Tumor Cells, Cultured
D000276:Adjuvants, Immunologic; D015295:Antigens, Tumor-Associated, Carbohydrate; D001500:BCG Vaccine; D019496:Cancer Vaccines; D007074:Immunoglobulin G; D009077:Mucins; C040286:Tn antigen